Gene Therapy Market - Global Forecast 2025-2032

Gene therapy is establishing itself as a cornerstone in modern therapeutics, offering tailored solutions across diverse clinical areas. Through continued technological advances and integration into evolving healthcare frameworks, it is becoming central to the strategies of global life sciences organizations and medical providers.

Market Snapshot: Gene Therapy Market Size and Growth Prospects

The gene therapy market expanded from USD 10.31 billion in 2024 to USD 12.91 billion by 2025 and is projected to reach USD 75.92 billion in 2032 with a CAGR of 28.33%. This trajectory is underpinned by rapid clinical advancements and stronger integration of translational science. Expansion is no longer confined to rare diseases; major uptake in oncology and cardiology is accelerating sector maturity. Multiplying stakeholders—from biopharmaceutical leaders to contract research organizations—are positioning to harness emerging regulatory policies, funding channels, and scientific breakthroughs. Market complexity is increasing as geographic adoption widens and new end users enter the ecosystem.

Scope & Segmentation of the Gene Therapy Market

• Vector Type: Covers both non-viral innovations (lipofection, plasmid DNA) and viral vectors (adeno-associated, adenovirus, retrovirus, herpes simplex virus), driving precise cell targeting.
• Treatment Modality: Addresses germline and somatic cell therapy, along with gene augmentation and suppression, offering options tailored to specific disorders.
• Target Genome: Encompasses DNA and RNA modifications, supporting therapy development across a range of pathologies.
• Delivery Mode: Incorporates ex vivo and in vivo approaches, enabling disease-oriented and patient-specific application.
• Route of Administration: Includes intramuscular, intraocular, and intravenous techniques, providing flexibility for clinical protocols.
• Patient Type: Targets both adult and pediatric populations, with consideration for differing clinical, ethical, and regulatory requirements.
• Therapeutic Area: Spans cardiovascular diseases, infectious diseases, monogenic disorders, and a broad spectrum of cancers, reflecting expanded market relevance.
• End-User: Engages contract research firms, healthcare providers, pharmaceutical and biotech companies, and research institutes, each influencing gene therapy adoption and deployment.
• Region: Encompasses key global areas such as the Americas, Europe, Middle East and Africa, and Asia-Pacific, capturing both developed and emerging market dynamics.
• Leading Companies: Features prominent organizations including Abeona Therapeutics, Amgen, Astellas Pharma, bluebird bio, Editas Medicine, Roche, Novartis, Gilead Sciences, Johnson & Johnson, and CRISPR Therapeutics, exemplifying a mix of multinationals and focused innovators.

Key Takeaways: Strategic Insights Shaping the Gene Therapy Ecosystem

• Refined vector engineering and evolving genome editing tools, such as CRISPR and base editors, are promoting application across diverse disease categories and advancing current treatment capabilities.
• Global efforts to streamline regulatory processes are reducing time-to-market for therapeutic candidates and fostering sustained trial activity, impacting the commercial landscape.
• Adoption of modular manufacturing and digital quality controls is enabling scalable production models, improving access for wider patient segments and adapting to demand fluctuations.
• Expanding use of collaborative models, including public-private partnerships and cross-border agreements, is increasing innovation potential and diversifying competition between established and new entrants.
• The shift toward value-based pricing and outcome-oriented reimbursement frameworks is influencing access and adoption, as healthcare systems evaluate cost-effectiveness and long-term impact.

Tariff Impact: United States Policy and Global Supply Chain Realignment

In 2025, new tariffs on critical inputs—such as viral vectors and single-use bioprocessing technologies—led to increased operational costs for the gene therapy sector in the United States. Companies responded by diversifying supply chains, ramping up local manufacturing, and forging fresh international partnerships. These adjustments are strengthening domestic supply resilience and sustaining clinical pipelines despite ongoing policy shifts.

Methodology & Data Sources

This analysis is based on insights from executive interviews, consultations with regulatory specialists, and an array of peer-reviewed publications and corporate financial documents. Findings are validated through a blend of data triangulation and domain expert review to ensure reliability for strategic planning.

Why This Report Matters

• Offers granular analysis of market structure, supporting evidence-based investment decisions, R&D strategy, and positioning against competitors.
• Enables senior decision-makers to proactively align with regulatory trends, technology adoption, and supply chain strategies to advance business objectives.
• Delivers actionable segmentation and company intelligence to inform both operational and commercial decisions within a rapidly progressing industry.

Conclusion

Gene therapy is driving significant transformation across healthcare. This report empowers senior leaders to navigate evolving dynamics, capture strategic opportunities, and optimize organizational response in a complex marketplace.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.